[go: up one dir, main page]

TNSN01123A1 - Formes posologiques nouvelles a liberation controlee - Google Patents

Formes posologiques nouvelles a liberation controlee

Info

Publication number
TNSN01123A1
TNSN01123A1 TNTNSN01123A TNSN01123A TNSN01123A1 TN SN01123 A1 TNSN01123 A1 TN SN01123A1 TN TNSN01123 A TNTNSN01123 A TN TNSN01123A TN SN01123 A TNSN01123 A TN SN01123A TN SN01123 A1 TNSN01123 A1 TN SN01123A1
Authority
TN
Tunisia
Prior art keywords
controlled release
core
dosage forms
water
new dosage
Prior art date
Application number
TNTNSN01123A
Other languages
English (en)
Inventor
Elizabeth Appel Leah
C Babcock Walter
Arthur Beyerinck Ronald
Brian Chidlaw Mark
John Curatolo William
Thomas Friesen Dwayne
Max Herbig Scott
Govind Thombre Avinash
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN01123A1 publication Critical patent/TNSN01123A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE UNE FORME POSOLOGIQUE A LIBERATION CONTROLEE (10). ELLE COMPREND UN NOYAU ENROBE, LE NOYAU (14,16) COMPRENANT UNE COMPOSITION CONTENANT UN MEDICAMENT (14) ET UNE COMPOSITION POUVANT GONFLER DANS L'EAU (16), CHACUNE OCCUPANT UNE REGION DISTINCTE DANS LEDIT NOYAU. L'ENROBAGE (18) AUTOUR DUDIT NOYAU EST PERMEABLE A L'EAU ET INSOLUBLE DANS L'EAU ET COMPORTE AU MOINS UN ORIFICE DE LIBERATION (20). APPLICATION : LIBERATION CONTROLEE D'UN AGENT BENEFIQUE OU D'UN MEDICAMENT DANS UN ENVIRONNEMENT D'UTILISATION.
TNTNSN01123A 2000-08-09 2001-08-08 Formes posologiques nouvelles a liberation controlee TNSN01123A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22419900P 2000-08-09 2000-08-09

Publications (1)

Publication Number Publication Date
TNSN01123A1 true TNSN01123A1 (fr) 2005-11-10

Family

ID=22839665

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN01123A TNSN01123A1 (fr) 2000-08-09 2001-08-08 Formes posologiques nouvelles a liberation controlee

Country Status (30)

Country Link
US (2) US20030086972A1 (fr)
EP (1) EP1326587A2 (fr)
JP (1) JP2004505907A (fr)
KR (1) KR20030024844A (fr)
CN (1) CN1461212A (fr)
AP (1) AP2001002237A0 (fr)
AU (1) AU2002229141A1 (fr)
BG (1) BG107538A (fr)
BR (1) BR0113067A (fr)
CA (1) CA2418907A1 (fr)
DO (1) DOP2001000229A (fr)
EA (1) EA200300081A1 (fr)
EC (1) ECSP034455A (fr)
EE (1) EE200300055A (fr)
GT (1) GT200100161A (fr)
HR (1) HRP20030082A2 (fr)
HU (1) HUP0300722A2 (fr)
IL (1) IL154012A0 (fr)
IS (1) IS6686A (fr)
MA (1) MA26939A1 (fr)
MX (1) MXPA03001209A (fr)
NO (1) NO20030627L (fr)
OA (1) OA12365A (fr)
PA (1) PA8524901A1 (fr)
PE (1) PE20020307A1 (fr)
PL (1) PL360658A1 (fr)
SV (1) SV2002000586A (fr)
TN (1) TNSN01123A1 (fr)
UY (1) UY26876A1 (fr)
WO (1) WO2002011702A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (fr) 1998-05-12 1999-11-17 Schwarz Pharma Ag Dérivés de 3,3-diphénylpropylamines
NZ518281A (en) * 1999-12-23 2005-01-28 Pfizer Prod Inc Controlled release drug dosage core comprising a drug-containing composition and a water-swellable composition
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
ATE508738T1 (de) 2001-01-12 2011-05-15 Sun Pharma Advanced Res Co Ltd System zur beabstandeten abgabe von arzneimitteln
NZ532097A (en) 2001-09-28 2006-02-24 Mcneil Ppc Inc Dosage forms having an inner core and outer shell
AU2003269744A1 (en) * 2002-05-15 2003-12-02 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
ES2529180T3 (es) * 2002-09-20 2015-02-17 Andrx Labs Llc Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
EP2255795A1 (fr) * 2002-09-28 2010-12-01 McNeil-PPC, Inc. Forme pharmaceutique à libération immédiate comprenant une coque dotée d'ouvertures
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
AR040157A1 (es) * 2003-06-06 2005-03-16 Rodriguez Julio Cesar Una formulacion en microgranulos para administracion oral en suspension acuosa
CA2534371A1 (fr) * 2003-08-04 2005-02-10 Pfizer Products Inc. Formes posologiques d'inhibiteurs de la proteine de transfert d'ester de cholesteryle et d'inhibiteurs de la hmg-coa-reductase
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
EP1845953A1 (fr) * 2005-02-03 2007-10-24 Pfizer Products Incorporated Formes de dosage assurant la liberation controlee et instantanee d'inhibiteurs de proteines de transfert d'ester de cholesteryle et la liberation instantanee d'inhibiteurs de hmg-coa reductase
US20060228413A1 (en) * 2005-02-28 2006-10-12 Penwest Pharmaceuticals Co. Controlled release venlafaxine formulations
US20080213381A1 (en) * 2005-03-14 2008-09-04 Pharmaceutical Industries Limited Oral Drug Delivery System
CA2600736A1 (fr) * 2005-03-16 2006-09-21 Dr. Reddy's Laboratories Ltd. Systeme d'administration pour de multiples medicaments
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
CN100448433C (zh) * 2005-09-21 2009-01-07 广州贝氏药业有限公司 一种克拉霉素肠溶药物组合物
WO2007124372A2 (fr) * 2006-04-20 2007-11-01 Transport Pharmaceuticals, Inc. Formules pharmaceutiques pour livraison iontophorétique de méthotrexate
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
BRPI0908114A2 (pt) * 2008-02-15 2015-10-06 Sun Pharma Advanced Res Co Ltd tabuleta oral de liberação controlada
CN102711741A (zh) * 2009-11-09 2012-10-03 比利时胶囊公司 递送载体
JP5390014B2 (ja) 2010-03-19 2014-01-15 第一三共株式会社 抗凝固剤の溶出改善方法
JPWO2013022059A1 (ja) * 2011-08-10 2015-03-05 第一三共株式会社 ジアミン誘導体含有医薬組成物
HUE045625T2 (hu) * 2013-01-30 2019-12-30 Daewoong Co Ltd Gyógyászati kompozíciók sebek védelmére, vérpangás szolgáltatására, vagy összetapadás megakadályozására a gyomor- és bél traktusban
MA41868A (fr) * 2015-04-01 2018-02-06 Spectrum Brands Inc Pastille retard et procédés s'y rapportant
US10350822B1 (en) * 2018-01-09 2019-07-16 Triastek Inc. Dosage forms with desired release profiles and methods of designing and making thereof
CN111867562B (zh) * 2018-03-07 2023-07-07 陈献 不溶性药物的水性制剂
UY39790A (es) * 2021-05-28 2023-01-31 Amgen Inc Formulaciones de apremilast
CN113600179B (zh) * 2021-09-16 2023-07-04 山东博霖环保科技发展有限公司 一种脱硝催化剂及其制备方法
TW202325285A (zh) * 2021-10-14 2023-07-01 靜岡縣公立大學法人 粉末製劑

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1025765B (it) * 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
US4187617A (en) * 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
JPH05178763A (ja) * 1991-02-19 1993-07-20 Nippon Saafuakutanto Kogyo Kk 難溶解性薬物溶解剤組成物
ATE209497T1 (de) * 1994-05-06 2001-12-15 Pfizer Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
NZ513456A (en) * 1997-07-01 2003-02-28 Pfizer Sertraline acetate, L-lactate and L-aspartate, processes for their preparation and their uses in psychotic disorders
WO1999001120A1 (fr) * 1997-07-01 1999-01-14 Pfizer Products Inc. Compositions de sertraline solubilisee
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
AP2001002119A0 (en) * 1998-10-13 2001-03-22 Pfizer Prod Inc Sertraline oral concentrate.
EP1027888B1 (fr) * 1999-02-10 2009-06-10 Pfizer Products Inc. Dispositif osmotique pour délivrer des dispersions solides amorphes des médicaments
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
UY26615A1 (es) * 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
RU2308263C2 (ru) * 2002-12-11 2007-10-20 Пфайзер Продактс Инк. Контролируемое высвобождение активного вещества в среду с высоким содержанием жира

Also Published As

Publication number Publication date
BG107538A (bg) 2003-11-28
WO2002011702A2 (fr) 2002-02-14
PL360658A1 (en) 2004-09-20
EP1326587A2 (fr) 2003-07-16
PA8524901A1 (es) 2002-04-25
HUP0300722A2 (hu) 2003-11-28
EE200300055A (et) 2004-12-15
CA2418907A1 (fr) 2002-02-14
NO20030627L (no) 2003-04-08
AU2002229141A1 (en) 2002-02-18
DOP2001000229A (es) 2002-09-30
OA12365A (en) 2006-05-16
HRP20030082A2 (en) 2003-04-30
MA26939A1 (fr) 2004-12-20
SV2002000586A (es) 2002-10-24
CN1461212A (zh) 2003-12-10
ECSP034455A (es) 2003-03-10
NO20030627D0 (no) 2003-02-07
JP2004505907A (ja) 2004-02-26
IS6686A (is) 2003-01-16
UY26876A1 (es) 2002-03-22
WO2002011702A3 (fr) 2002-11-28
MXPA03001209A (es) 2003-06-30
BR0113067A (pt) 2003-07-01
IL154012A0 (en) 2003-07-31
KR20030024844A (ko) 2003-03-26
US20030086972A1 (en) 2003-05-08
EA200300081A1 (ru) 2003-08-28
AP2001002237A0 (en) 2001-09-30
PE20020307A1 (es) 2002-04-23
GT200100161A (es) 2002-03-22
US20040052845A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
TNSN01123A1 (fr) Formes posologiques nouvelles a liberation controlee
TNSN00253A1 (fr) Forme posologique de medicament a liberation controlee
TNSN00251A1 (fr) Forme posologique de sertraline stratifiee commandee par hydrogel
WO2004108067A3 (fr) Systeme de distribution de medicaments programme
PT1028707E (pt) Formulacoes oftalmicas de libertacao controlada contendo medicamentos soluveis em agua
WO2005072079A3 (fr) Enrobage de medicaments a charge medicamenteuse elevee et procedes de fabrication
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
DE69942154D1 (de) Medikamenthaltige zusammensetzung in aerosolform
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
WO2004058837A3 (fr) Copolymere ampholytique et son utilisation
ID24818A (id) Komposisi farmasi yang digunakan pada selaput lendir
AP2004003046A0 (en) Dosage regimen and pharmaceutical composition for emergency contraception.
EP1354602A4 (fr) Compositions medicinales contenant un diuretique et un agent renforcant la resistance a l'insuline
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
KR940008674A (ko) 경구용 약제
DE60108354D1 (de) 2H-1-Benzopyran-Derivative, Prozesse zu ihrer Herstellung und Pharmazeutische Zusammensetzungen
DZ2564A1 (fr) Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés.
GEP20043377B (en) Pharmaceutical Complex
IT1306179B1 (it) Composizione per la prevenzione e cura delle disfunzioni e patologierenali di tipo tossico e funzionale.
WO2002036105A3 (fr) Utilisation d'agents sequestrants de cortisol dans le cadre du traitement de troubles lies a l'hypercortisolemie
UY26503A1 (es) " forma de dosificación de fármacos accionada por un hidrogel"
ECSP003856A (es) Forma de dosificacion de farmaco en capas impulsada por hidrogel
KR970702054A (ko) 헬리코박터 파이로리에 기인한 위장 기능장해 치료를 위한 스피라마이신의 용도(use of spiramycin for treating gastrointestinal disorders caused by h. pylori)
AU2001295839A1 (en) Use of agents active against candida in the treatment of disorders of the oral and intestinal mucosa